Free Trial
OTCMKTS:RGIN

Regenicin (RGIN) Stock Price, News & Analysis

Regenicin logo

About Regenicin Stock (OTCMKTS:RGIN)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
100,000 shs
Market Capitalization
$20 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive RGIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regenicin and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RGIN Stock News Headlines

History
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
Regenicin, Inc. (RGIN)
LGBT+ History Month - Teaching Resources
History of Walmart: Timeline and Facts
See More Headlines

RGIN Stock Analysis - Frequently Asked Questions

Regenicin Inc. (OTCMKTS:RGIN) issued its earnings results on Wednesday, August, 19th. The company reported $0.00 earnings per share (EPS) for the quarter.

Shares of RGIN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Regenicin investors own include Energous (WATT), Cheniere Energy (LNG), Vital Therapies (VTL), Leafbuyer Technologies (LBUY).

Company Calendar

Last Earnings
8/19/2020
Today
5/05/2026
Fiscal Year End
9/30/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Medical Equipment
Current Symbol
OTCMKTS:RGIN
CIK
1412659
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
165,770,000
Free Float
N/A
Market Cap
$20 thousand
Optionable
Not Optionable
Beta
-25.00
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (OTCMKTS:RGIN) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners